Latest fiscal year 2025 · computed deterministically from XBRL 10-K data · coverage 100%
In fiscal 2025, SINOVAC BIOTECH LTD reported revenue of $386M, up 6.8% year over year. Operating margin was -127.0% and net margin -51.5%, on a free-cash-flow margin of -145.4% with capital expenditure at 12.7% of revenue. Every figure is computed directly from SVA's SEC XBRL 10-K filing — deterministic, with no estimates.
| Fiscal year | Revenue | Op margin | Net margin |
|---|---|---|---|
| FY2025 | $386M | -127.0% | -51.5% |
| FY2024 | $361M | -139.9% | 11.3% |
| FY2023 | $470M | -151.9% | -2.9% |
| FY2022 | $1.47B | -34.5% | 1.0% |
| FY2021 | $19.37B | 91.0% | 41.9% |
How does SVA compare against its actual peer set?
A CompsDesk subscription covers unlimited benchmark packs on any covered company: up to 19 metrics (6 core guaranteed) × up to 5 fiscal years × up to 12 chosen peers, percentile placement, the subject's figures cited to their SEC tag, form and period with every company identified by its CIK, PDF-ready HTML + CSV, generated on demand.
Related in the same sector: AAWH · ABBV · ABCL · ABT · ABUS · ACAD
Source: SEC EDGAR XBRL (10-K filings), latest filed values. "n/a" = not disclosed under mapped tags — never estimated. Informational benchmarking, not investment advice. © CompsDesk / Sam Arora.